Amaç: Subakut sklerozan panensefalit (SSPE), kızamık hastalığının geç başlangıçlı kronik ve mortal seyreden bir komplikasyonudur. SSPE hastalığından korunma, kızamık aşısı ile kızamık hastalığından korunmaya bağlıdır. Aşı kararsızlığına neden olan sebeplerin başında gelen yetersiz bilgi edinme ve güven sorunu; SSPE ilişkili medikolegal sürece yansıyan olgularda da sıklıkla karşımıza çıkmaktadır. Gereç ve Yöntemler: Araştırma, tanımlayıcı bir çalışma olarak planlanmış, Ocak 2017- Aralık 2020 tarihleri arasında Adli Tıp 7. İhtisas Kurulu tarafından düzenlenen 16.714 rapor (mütalaa ve müzekkere) retrospektif olarak taranmış; 'SSPE' tanısı ile tıbbi uygulama hatası iddiası bulunan 6 olgu çalışmaya dâhil edilmiştir. Bulgular: Çalışmaya dâhil edilen SSPE olgularının 5'i (%83,3) erkek, 1'i (%16,6) kız olup, olguların yaş aralığı 5-17 (medyan: 10) idi. Tüm olgularda tıbbi uygulama hatası iddiası; aşılama süreci ile ilgilidir. Tüm olgularda davalı taraf Sağlık Bakanlığıdır. Tüm olgular en az 1 doz kızamık aşısı ile aşılanmış olup, ilk doz aşılamaları 9. ayda yapılmıştır. Olguların klinik başvuruları değerlendirildiğinde; ortalama tanı yaşı 10 olarak saptanırken; 1 olgunun ateş, hâlsizlik, 1 olgunun konuşma bozukluğu, 4 (%66,6) olgunun ise yürüme ve denge bozukluğu ile sağlık kuruluşuna başvurduğu görülmüştür. Olgular hakkında düzenlenen Adli Tıp Kurumu 7. Adli Tıp İhtisas Kurulu Sonuçları değerlendirildiğinde 5 (%83,3) olguda, SSPE hastalığının kızamık hastalığının uzun dönem komplikasyonlarından biri olduğu vurgulanmış olduğu ve sağlık çalışanlarına ait tıbbi uygulama hatası bulunmadığı görülmüştür. Sonuç: Çalışmamızda, medikolegal sürece konu olan iddialar değerlendirildiğinde aşının kendinin suçlanmadığı görülmüştür. Bu durum ülkemizde çocukluk çağı aşılarına karşı toplumsal duyarlılığın ve güvenin devam ettiğini göstermekle birlikte bu alanda yeni çalışmalar yapılmasına ihtiyaç vardır.
Anahtar Kelimeler: Aşı; subakut sklerozan panensefalit; tıbbi uygulama hatası
Objective: Subacute sclerosing panencephalitis (SSPE) is a late-onset chronic and mortal complication of measles. Protection from SSPE disease depends on prevention of measles disease with measles vaccine. Insufficient information and trust problems are the leading causes of vaccine instability. This situation is frequently encountered in cases with a diagnosis of SSPE, which is reflected in the medicolegal process. Material and Methods: The research was planned as a descriptive study. 16,714 reports (opinions and warrants) prepared by the 7th Specialization Board of Forensic Medicine between January 2017 and December 2020 were evaluated retrospectively. Six cases with "SSPE" diagnosis and alleged medical malpractice were included in the study. Results: Gender distribution of the SSPE cases, 5 boys (83.3%) and 1 girl (16.6%). The age range of the cases was 5-17 (median: 10). Alleged medical malpractice in all cases; It is related to the vaccination process and the defendant party is the Ministry of Health. All cases were vaccinated with at least one dose of measles vaccine. The first dose vaccination of the cases was done in the 9th month. When the clinical applications of the cases are evaluated; the average age at diagnosis was 10. Considering the clinical presentations of the cases; 1 case fever, weakness, 1 case speech disorder, 4 cases (66.6%) gait and balance disorder. When the reports of the 7th Specialization Board of the Council of Forensic Medicine in 5 (%83.3) cases, it was emphasized that SSPE disease was one of the longterm complications of measles and it was observed that there was no medical malpractice of healthcare professionals. Conclusion: In our study, when the allegations regarding the medicolegal process were evaluated, it was seen that the vaccine itself was not blamed. Although this shows that social sensitivity and trust towards childhood vaccines continue in our country, there is a need for new studies in this area.
Keywords: Vaccine; subacute sclerosing panencephalitis; malpractice
- Wendorf KA, Winter K, Zipprich J, Schechter R, Hacker JK, Preas C, et al. Subacute sclerosing panencephalitis: The devastating measles complication that might be more common than previously estimated. Clin Infect Dis. 2017;65(2):226-32. [Crossref] [PubMed]
- Garg RK, Mahadevan A, Malhotra HS, Rizvi I, Kumar N, Uniyal R. Subacute sclerosing panencephalitis. Rev Med Virol. 2019;29(5): e2058. [Crossref] [PubMed]
- Saurabh K, Singh V, Pathak A, Chaurasia R. Subacute sclerosing pan encephalitis: An update. Journal of Clinical and Scientific Research. 2021;10(1):35-42. [Link]
- Rocke Z, Belyayeva M. Subacute Sclerosing Panencephalitis. 2020 Jul 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. [PubMed]
- Mekki M, Eley B, Hardie D, Wilmshurst JM. Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol. 2019;61(10):1139-44. [Crossref] [PubMed]
- Hidayah N, Wijaya AB. Diagnostic approaches and management of subacute sclerosing panencephalitis in children. Berkala Kedokteran. 2020;16(2):141-8. [Crossref]
- Khetsuriani N, Sanadze K, Abuladze M, Tatishvili N. High risk of subacute sclerosing panencephalitis following measles outbreaks in Georgia. Clin Microbiol Infect. 2020;26(6): 737-42. [Crossref] [PubMed]
- Enders-Ruckle G. Frequency, serodiagnosis and epidemiological features of subacute sclerosing panencephalitis (SSPE) and epidemiology and vaccination policy for measles in the Federal Republic of Germany (FRG). Dev Biol Stand. 1978;41:195-207. [PubMed]
- Pittet LF, Posfay-Barbe KM. Increasing incidence of subacute sclerosing panencephalitis in infants: a collateral effect of under-vaccination. Clin Microbiol Infect. 2020;26(6):662-4. [Crossref] [PubMed]
- Sharma N, Dhole D, Rai R, Inamdar P, Elon N. Thinking measles unconventionally, SSPE-why we must vaccinate. International Journal of Science and Research. 2020;9(1):1177-80. [Link]
- Billauer BP. The 2018-2019 measles epidemic: using the law as a public health response. SSRN. 2020:53. [Crossref]
- Tosun S, Olut AI, Tansug N. Adverse effects of single-component measles vaccine in school children. Vaccine. 2017;35(52):7309-11. [Crossref] [PubMed]
- Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4(4): CD004407. [Crossref] [PubMed] [PMC]
- Witman Tsur S, Adrian Zaher E, Tsur M, Kania K, Kalinowska-Łyszczarz A. Current immunological and clinical perspective on vaccinations in multiple sclerosis patients: are they safe after all? Int J Mol Sci. 2021;22(8):3859. [Crossref] [PubMed] [PMC]
- Measles vaccines: WHO position paper-April 2017. Wkly Epidemiol Rec. 2017;92(17):205-27. English, French. [PubMed]
- McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 2013;62(4):1-34. [Link]
- Quinn SC, Jamison AM, Freimuth VS. Measles outbreaks and public attitudes towards vaccine exemptions: some cautions and strategies for addressing vaccine hesitancy. Hum Vaccin Immunother. 2020;16(5): 1050-4. [Crossref] [PubMed] [PMC]
- Dubé È, Ward JK, Verger P, MacDonald NE. Vaccine hesitancy, acceptance, and anti-vaccination: trends and future prospects for public health. Annu Rev Public Health. 2021;42:175-91. [Crossref] [PubMed]
- Jacobson RM, St Sauver JL, Finney Rutten LJ. Vaccine hesitancy. Mayo Clin Proc. 2015;90(11):1562-8. [Crossref] [PubMed]
- Pallivathucal LB, Noymer A. Subacute sclerosing panencephalitis mortality, United States, 1979-2016: Vaccine-induced declines in SSPE deaths. Vaccine. 2018;36(35):5222-5. [Crossref] [PubMed]
- Yörük S. Factors associated with childhood vaccine hesitancy and measles vaccine hesitancy among healthcare students. Nursing & Health Sciences. 2020;22(4):1030-7. [Crossref] [PubMed]
- Goraya J, Marks H, Khurana D, Legido A, Melvin J. Subacute sclerosing panencephalitis (SSPE) presenting as acute disseminated encephalomyelitis in a child. J Child Neurol. 2009;24(7):899-903. [Crossref] [PubMed]
- Koç S. Adli tıbbi açıdan malpraktis ve hekim sorumluluğu [Forensic medicine related physician liability and malpractice]. Bulletin of Thoracic Surgery. 2014;5(1):14-22. [Crossref]
- Koç S. Yasal düzenlemeler çerçevesinde hekim sorumluluğu [Responsibility and obligations of physician by legal regulations]. Türkderm. 2007;41:33-8. [Link]
- Tuğcu H, Yorulmaz C, Koç S. Hekim sorumluluğu ve tıbbi malpraktis. Koç S, Can M, editörler. Birinci Basamakta Adli Tıp. 2. Baskı. İstanbul: TTB İstanbul Tabip Odası Yayınları; 2010. p.9-17. [Link]
- Dyken PR. Clinical expressivity in resurging SSPE: changing age of onset and new early symptoms. Journal of Pediatric Neurology. 2004;2(2):53-6. [Link]
- Jović NJ. Epilepsy in children with subacute sclerosing panencephalitis. Srp Arh Celok Lek. 2013;141(7-8):434-40. [Crossref] [PubMed]
- Hergüner MO, Altunbaşak S, Baytok V. Patients with acute, fulminant form of SSPE. Turk J Pediatr. 2007;49(4):422-5. [PubMed]
- Nwangwu CC, Chike AE, Eucharia Ijeoma IO. Cross-sectional survey on parental perception and attitude on measles vaccine: Low hospital measles case presentation in rural area in enugu Nigeria. Journal of Clinical & Diagnostic Research. 2021;15(2). [Crossref]
- Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007;36(6):1334-48. [Crossref] [PubMed]
.: İşlem Listesi